Bringing Together Diverse Organizations to Strive for Health Equity
Pfizer and over 40 U.S. nonprofit partners are working toward health equity by closing gaps in healthcare that impact historically
overlooked communities.
Pfizer's ELREXFIOTM Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma
ELREXFIO is the first off‐the‐shelf (ready‐to‐use) fixed‐dose subcutaneous BCMA‐directed agent in
the U.S. with the option for every‐other‐week long‐term dosing after 24 weeks of weekly treatment.
